Clinical Trial News and Research

RSS

Thalidomide analog shows promise against sickle cell disease

A thalidomide analog is shaping up as a safe, worthy opponent of sickle cell disease, Georgia Health Sciences University researchers report.

19 Jul 2011

Sherpa opens new CGMP production facility in San Diego

Sherpa Clinical Packaging, a privately held provider of Clinical Trial Material management services, hosted a ribbon cutting ceremony today to mark the opening of its newly constructed state-of-the-art, CGMP production facility in San Diego, CA.

19 Jul 2011

LLS awards new SCOR grants valued at $12.5M for research in lymphoma and myeloproliferative neoplasms

The Leukemia & Lymphoma Society (LLS) today announced it has awarded two new Marshall A. Lichtman Specialized Center of Research (SCOR) grants to Frederick W. Alt, Ph.D., Harvard Medical School, and Anthony Green, M.D., Ph.D., University of Cambridge. Each SCOR is valued at $1.25 million a year for five years for a total of $6.25 million.

18 Jul 2011

IHD blood test for Alzheimer's disease yields 83% sensitivity and 82% specificity

Innovative Health Diagnostics (IHD), the innovative company specialising in the development of diagnostic blood tests for Alzheimer's disease and neurodegenerative illnesses presents its first clinical results for its IHD-Amy blood test for Alzheimer's disease.

18 Jul 2011

Upsher-Smith initiates USL261 ARTEMIS1 Phase III study for seizure clusters in epilepsy patients

Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted orphan drug designation for this use by the Food and Drug Administration (FDA).

18 Jul 2011

Study: IL-2 monotherapy not effective as maintenance therapy for acute myeloid leukemia

EpiCept Corporation announced today the publication of a new meta-analysis which concluded that interleukin-2 (IL-2) monotherapy is not effective as a maintenance therapy for acute myeloid leukemia (AML) patients in first complete remission. These results were published in the July 7, 2011 edition of Blood, a leading scientific journal in hematology.

18 Jul 2011

FDA approves Shire's Lialda for maintenance of remission of ulcerative colitis

Shire plc, the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Lialda® (mesalamine) Delayed Release Tablets for the maintenance of remission in patients with ulcerative colitis.

18 Jul 2011

SEEK HIV-v vaccine demonstrates 90% reduction in HIV viral load

SEEK, a privately owned biopharmaceutical company specializing in immunology, announces today that it has completed a Phase Ib/II clinical trial of its HIV-v vaccine which demonstrates a one log (approx 90 percent) difference in viral count in HIV-infected people compared with the placebo group, after just a single vaccine injection.

18 Jul 2011

New ways for treating diabetes

Surgeons at NewYork-Presbyterian Hospital/Columbia University Medical Center are innovating new ways to treat diabetes using techniques from weight-loss surgery, including experimental procedures to improve blood glucose levels and address a major complication of the disease.

16 Jul 2011

Inovio reports strong immune responses with VGX-3100 vaccine for cervical dysplasia and cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of T cell immune responses of up to over two years (at the latest time measured) in 7 of 8 evaluated patients following a fourth vaccination of VGX-3100, its investigational SynCon® DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV) that is delivered using intramuscular electroporation.

15 Jul 2011

UTHealth enrolls first patient in new stem cell therapy trial for ischemic stroke

The first Texas patient has been enrolled by researchers at The University of Texas Health Science Center at Houston in the country's first double-blind clinical trial studying the safety and efficacy of an innovative stem cell therapy that can be given up to 19 days after an ischemic stroke.

15 Jul 2011

Meditation appears to change brain anatomy: Study

Two years ago, researchers at UCLA found that specific regions in the brains of long-term meditators were larger and had more gray matter than the brains of individuals in a control group. This suggested that meditation may indeed be good for all of us since, alas, our brains shrink naturally with age.

15 Jul 2011

NeoStem to acquire Amorcyte

NeoStem, Inc., an international biopharmaceutical company, announced the signing of a definitive merger agreement whereby NeoStem will acquire Amorcyte, Inc., a development stage cell therapy company focusing on novel treatments for cardiovascular disease.

15 Jul 2011

inVentiv Health announces completion of PharmaNet acquisition

inVentiv Health, offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced it has completed the acquisition of PharmaNet Development Group, Inc., a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries.

14 Jul 2011

USPTO awards patent for Convergen LifeSciences' CNVN202 to treat lung cancer

Convergen LifeSciences, Inc. announced today that another United States Patent 7,977,468 has been awarded by the U.S. Patent and Trademark Office jointly to The University of Texas System Board of Regents and The Secretary, U.S. Department of Health and Human Services.

14 Jul 2011

Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation.

14 Jul 2011

RXi expands intellectual property portfolio with additional NeuVax patents

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced today that it expanded its patent portfolio with additional patents covering worldwide rights to develop and commercialize NeuVax.

14 Jul 2011

BIOTRONIK begins comparative study of ORSIRO stent with Abbott's XIENCE PRIME stent

BIOTRONIK announced today the start of an international study comparing the company's ORSIRO sirolimus-eluting coronary stent with Abbott Laboratory's XIENCE PRIME everolimus-eluting coronary stent. The first implantations in the study, called BIOFLOW-II, took place in Europe last week.

14 Jul 2011

SAS expands Global Certification Program offerings

SAS, the leader in business analytics software and services and the de facto industry standard for clinical data analysis and reporting in the life sciences/pharmaceutical industry, today expanded its Global Certification Program offerings with the introduction of a new credential - SAS Certified Clinical Trials Programmer using SAS9.

14 Jul 2011

UCI study sheds light on how transplantation alleviates side effects of radiotherapy

Human neural stem cells are capable of helping people regain learning and memory abilities lost due to radiation treatment for brain tumors, a UC Irvine study suggests.

14 Jul 2011

Clinical Trial News and Research

Thalidomide analog shows promise against sickle cell disease

Sherpa opens new CGMP production facility in San Diego

LLS awards new SCOR grants valued at $12.5M for research in lymphoma and myeloproliferative neoplasms

IHD blood test for Alzheimer's disease yields 83% sensitivity and 82% specificity

Upsher-Smith initiates USL261 ARTEMIS1 Phase III study for seizure clusters in epilepsy patients

Study: IL-2 monotherapy not effective as maintenance therapy for acute myeloid leukemia

FDA approves Shire's Lialda for maintenance of remission of ulcerative colitis

SEEK HIV-v vaccine demonstrates 90% reduction in HIV viral load

New ways for treating diabetes

Inovio reports strong immune responses with VGX-3100 vaccine for cervical dysplasia and cancer

UTHealth enrolls first patient in new stem cell therapy trial for ischemic stroke

Meditation appears to change brain anatomy: Study

NeoStem to acquire Amorcyte

inVentiv Health announces completion of PharmaNet acquisition

USPTO awards patent for Convergen LifeSciences' CNVN202 to treat lung cancer

Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza

RXi expands intellectual property portfolio with additional NeuVax patents

BIOTRONIK begins comparative study of ORSIRO stent with Abbott's XIENCE PRIME stent

SAS expands Global Certification Program offerings

UCI study sheds light on how transplantation alleviates side effects of radiotherapy

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery